MDVN1003 is a potent inhibitor of BTK amd PI3K delta. MDVN1003 inhibits Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ), two proteins regulated by the B cell receptor (BCR) that drive the growth of many NHLs. MDVN1003 induces cell death in a B cell lymphoma cell line but not in an irrelevant erythroblast cell line. References: Alfaro J, Perez de Arce F, Belmar S, Fuentealba G, Avila P, Ureta G, Flores C, Acuna C, Delgado L, Gaete D, Pujala B, Barde A, Nayak AK, Upendra T, Patel D, Chauhan S, Sharma VK, Kanno S, Almirez RG, Hung DT, Chakravarty S, Rai R, Bernales S, Quinn KP, Pham SM, McCullagh E. Dual Inhibiton of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat non-Hodgkin's B cell Malignancies. J Pharmacol Exp Ther. 2017 Mar 15. pii: jpet.116.238022. doi: 10.1124/jpet.116.238022. [Epub ahead of print] PubMed PMID: 28298527.

纯度：≥98%

CAS：2058116-52-0